Working… Menu

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02536495
Recruitment Status : Withdrawn (PI decision due to funding support)
First Posted : September 1, 2015
Last Update Posted : October 30, 2015
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
Erin Bertino, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : December 2018
Study Completion Date : No date given